NARTIC is a biotechnological project emerged from the Laboratory of Translational Research in Child and Adolescents Cancer of the Vall d'Hebron Research Institute (VHIR), under the scientific leadership of Dr. Miquel Segura, principal investigator of this group. It has been selected by the Barcelona Activa Preeceleration Program to receive its support in the market entry process. This program offers everything necessary for projects with a high technological impact to enter the market with guarantees of success and is promoted by Barcelona Activa and co-financed by FEDER.NARTIC project aims to implement the RNA-based therapies into clinical practice in order to improve the poor outcome of patients with advanced cancer or unresponsive to current treatments. Thus, in the NARTIC project a novel nanocarrier, Quatsomes, has been designed and conjugated with a tumor suppressive miRNA for the treatment of cancer, such as high-risk neuroblastoma.The project team is formed by Dr. Miquel Segura, as the scientific leader, Dra. Ariadna Boloix as a scientific entrepreneur, two scientific advisors from Nanomol group (ICMAB-CSIC) and Martí Archs, as the innovation and technology transfer project manager.The participation of NARTIC Project in the incubation program of Barcelona Activa will allow to further reach nearly clinical stages of the project, define its business model, as well as kickstart their access to the market.